epilepsy drug Market Size, Share, and Industry Report [2031]

epilepsy drug Market Size, Share, and Industry Report [2031]

Segments - Epilepsy Drug Market by Treatments (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-2448 | 4.5 Rating | 83 Reviews | 196 Pages | Format : PDF Excel PPT

Report Description


The global epilepsy drug market size is projected to register a substantial CAGR during the forecast period, 2021-2018. The growth of the market is attributed to the anticipated launch of epilepsy drugs that are currently in the pipeline. The growth of the market is also attributed to the global increasing incidence of epilepsy cases along with the rising demand for third-generation anti-epileptics.

Global Epilepsy Drug Market Summary

Epilepsy is one of the most common disorders in which the brain’s nerve cell activity gets disturbed and causes seizures. Epilepsy is expected to occur when an individual acquires some brain injury such as stroke or trauma. It can also occur due to some genetic disorder. When an individual suffers from epilepsy their brain activity becomes abnormal which leads to loss of awareness, sensations, and behaving unusually. Epilepsy cannot be cured but can be controlled with the usage of drugs. Change in diet, devices, and surgery are also done in some cases to treat epilepsy. As per the reports by the Epilepsy Foundation of America, there are 65 million individuals are suffering from epilepsy across the globe among which the U.S, alone have 3.4 million individuals who develop epilepsy at some point in their life. Every year 150,000 new cases are registered in the U.S.

The COVID-19 pandemic had adverse impact on the epilepsy market as the development of epilepsy drugs for the treatment was severely disturbed due to sudden halt of the manufacturing units. Meanwhile, it is not sure whether epilepsy increase the risk of getting infected with COVID-19. No evidence is available that proves that people suffering from epilepsy have a weak immune system. However, there may be some factors that are anticipated to affect the immune system and increase the chances of being affected by COVID-19.

  • Increasing approvals of new drugs for the treatment of epilepsy in the past few years is a key factor driving the market growth expansion during the forecast period.
  • Availability of healthcare infrastructure in the developed region is another factor helping the market growth in the coming years.
  • Side effects caused due to the consumption of epilepsy drugs are estimated to act as a restraining factor that can hinder the market growth.
  • Recent expiration of patents of drugs by major brands is a key challenge that can hamper the market growth during the forecast period.
  • Rising initiatives to increase awareness of the disorder and rising number of people who are aware of early diagnostic of the disorder across the globe present key opportunities for the market expansion.

Scope of the Report

The report on the global epilepsy drug market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Epilepsy Drug Market – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatments (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Sanofi S.A; Cephalon, Inc.; Johnson & Johnson; Pfizer, Inc.; Eisai Co., Ltd.; Valeant Pharmaceuticals International, Inc.; Novartis AG; GlaxoSmithKline PLC.; Abbott Laboratories, Inc.; Sunovion Pharmaceuticals, Inc.; and UCB Pharma Ltd.

Market Segment Insights

Third generation anti-epileptics segment is anticipated to witness a rapid growth

On the basis of treatments, the global epilepsy drug market is divided into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third generation anti-epileptics segment is anticipated to witness a rapid growth during the forecast period attributed to the rising availability of these drugs and their deep penetration in the market. The third generation anti-epileptics include drugs such as lacosamide, eslicarbazepine, and retigabine. The first generation anti-epileptics include drugs such as carbamazepine, phenobarbital, valproate, primidone, and ethosuximide. Among these, carbamazepine is the most common drug prescribes by professionals for the treatment of partial and generalized seizures. These are key factors likely to boost the segment growth of the first generation. Meanwhile, the second generation anti-epileptics consist of drugs such as brivaracetam, perampanel, levetiracetam, and lamotrigine.

Global Epilepsy Drug Market Treatment

North America is expected to register a lucrative growth

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to register a lucrative growth during the forecast period attributed to ongoing research & development on a large scale, the launch of new anti-epileptic drugs, and the presence of favorable initiatives by various governments. However, the market of Asia Pacific is anticipated to expand at a robust growth rate in the coming years owing to the increasing level of awareness among the patients regarding the treatment of epilepsy and the presence of medical needs for highly unmet population in the region.  

Global Epilepsy Drug Market Region 

Segments

Segments Covered in the Report

The global epilepsy drug market has been segmented on the basis of

Treatments

  • First Generation Anti-Epileptics
  • Second Generation Anti-Epileptics
  • Third Generation Anti-Epileptics

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Sanofi S.A
  • Cephalon, Inc.
  • Johnson & Johnson
  • Pfizer, Inc.
  • Eisai Co., Ltd.
  • Valeant Pharmaceuticals International, Inc.
  • Novartis AG
  • GlaxoSmithKline PLC.
  • Abbott Laboratories, Inc.
  • Sunovion Pharmaceuticals, Inc.
  • UCB Pharma Ltd.

Competitive Landscape

Key players competing in the global epilepsy drug market are Sanofi S.A; Cephalon, Inc.; Johnson & Johnson; Pfizer, Inc.; Eisai Co., Ltd.; Valeant Pharmaceuticals International, Inc.; Novartis AG; GlaxoSmithKline PLC.; Abbott Laboratories, Inc.; Sunovion Pharmaceuticals, Inc.; and UCB Pharma Ltd. Many of these players have adopted business strategies such as the development of novel drugs, launching of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.

Global Epilepsy Drug Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. epilepsy drug Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. epilepsy drug Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. epilepsy drug Market - Supply Chain
  4.5. Global epilepsy drug Market Forecast
     4.5.1. epilepsy drug Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. epilepsy drug Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. epilepsy drug Market Absolute $ Opportunity
5. Global epilepsy drug Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. epilepsy drug Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global epilepsy drug Demand Share Forecast, 2019-2026
6. North America epilepsy drug Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America epilepsy drug Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America epilepsy drug Demand Share Forecast, 2019-2026
7. Latin America epilepsy drug Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America epilepsy drug Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America epilepsy drug Demand Share Forecast, 2019-2026
8. Europe epilepsy drug Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe epilepsy drug Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe epilepsy drug Demand Share Forecast, 2019-2026
9. Asia Pacific epilepsy drug Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific epilepsy drug Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific epilepsy drug Demand Share Forecast, 2019-2026
10. Middle East & Africa epilepsy drug Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa epilepsy drug Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa epilepsy drug Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global epilepsy drug Market: Market Share Analysis
  11.2. epilepsy drug Distributors and Customers
  11.3. epilepsy drug Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Sanofi S.A
     11.4.2. Cephalon, Inc.
     11.4.3. Johnson & Johnson
     11.4.4. Pfizer, Inc.
     11.4.5. Eisai Co., Ltd.
     11.4.6. Valeant Pharmaceuticals International, Inc.
     11.4.7. Novartis AG
     11.4.8. G

Methodology

Our Clients

The John Holland Group
Nestle SA
Microsoft
Deloitte
Dassault Aviation
General Electric
General Mills
Honda Motor Co. Ltd.